Screening for latent tuberculosis in migrants—status quo and future challenges

• DOI: 10.1016/j.ijid.2024.107002
• Publication Date: 2024-03-11T16:37:23Z
• Authors: Eskild Petersen; Seif Al-Abri; Amina Al-Jardani; Ziad A. Memish; Eleni Aklillu; Francine Ntoumi; Peter Mwaba; Christian Wejse; Alimuddin Zumla; Fatma Al-Yaquobi
• Keywords: Transients and Migrants; 0301 basic medicine; Tuberculin Test; Prevention; Tuberculosis/diagnosis; 610; Infectious and parasitic diseases; RC109-216; Migrants; Interferon-gamma Release Tests/methods; Treatment; 03 medical and health sciences; Mass Screening/methods; Latent Tuberculosis; Screening; Tuberculin Test/methods; Humans; Tuberculosis; Mass Screening; Latent Tuberculosis/diagnosis; Interferon-gamma Release Tests; Latent TB

To review the evidence that migrants from tuberculosis (TB) high-incidence countries migrating to TB low-incidence countries significantly contribute to active TB cases in the counties of destination, primarily through reactivation of latent TB.This is a narrative review. The different screening programs in the countries of destination are reviewed either based on screening and preventive treatment of latent TB pre or more commonly - post arrival.Screening can be performed using interferon-gamma release assays (IGRA) or tuberculin skin tests (TST). Preventive treatment of latent TB is using either monotherapy with isoniazid, or in combination with rifampicin or rifapentine. We discuss the ethical issues of preventive treatment in asymptomatic individuals and how these are addressed in different screening programs.Screening migrants from TB high endemic countries to TB low endemic countries is beneficial. There is a lack of standardization and agreement on screening protocols, follow up and treatment.